Public Employees Retirement System of Ohio Makes New Investment in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Public Employees Retirement System of Ohio acquired 38,507 shares of Arrowhead Pharmaceuticals valued at approximately $3.14 million. Institutional investors collectively own 62.61% of the company.
• Analysts remain broadly bullish, with nine Buy ratings, three Holds, and one Sell; the average price target is $98.42 versus the stock’s reported price of $86.34.
• Arrowhead’s quarterly revenue rose 171% year over year to $75.25 million, exceeding estimates, although the company reported a larger-than-expected loss of $1.36 per share.

Public Employees Retirement System of Ohio acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 38,507 shares of the biotechnology company's stock, valued at approximately $3,139,000.

Other institutional investors have also recently made changes to their positions in the company. Transamerica Financial Advisors LLC bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $6,309,000. Corient Private Wealth LP bought a new stake in shares of Arrowhead Pharmaceuticals during the second quarter valued at approximately $1,313,000. Ausdal Financial Partners Inc. purchased a new position in shares of Arrowhead Pharmaceuticals in the second quarter worth $385,000. Jupiter Topco LLC bought a new position in shares of Arrowhead Pharmaceuticals during the second quarter worth $99,623,000. Finally, Hsbc Holdings PLC purchased a new position in Arrowhead Pharmaceuticals during the second quarter valued at $16,765,000. Hedge funds and other institutional investors own 62.61% of the company's stock.

Insiders Place Their Bets

In other news, Director Michael Perry sold 11,600 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the sale, the director directly owned 111,459 shares of the company's stock, valued at approximately $9,730,370.70. The trade was a 9.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Adeoye Olukotun sold 2,000 shares of the firm's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the transaction, the director directly owned 31,600 shares in the company, valued at $2,747,936. This represents a 5.95% decrease in their position. The SEC filing for this sale provides additional information. 3.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have commented on ARWR. HC Wainwright reissued a "buy" rating and set a $120.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday. Stifel Nicolaus started coverage on Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They issued a "buy" rating and a $98.00 target price on the stock. JPMorgan Chase & Co. increased their price target on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. Chardan Capital reaffirmed a "buy" rating and issued a $115.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 31st. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 31st. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $98.42.

Arrowhead Pharmaceuticals Trading Down 0.2%

Shares of NASDAQ ARWR opened at $86.34 on Friday. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $27.10 and a fifty-two week high of $95.49. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90. The company has a market cap of $12.16 billion, a price-to-earnings ratio of -38.37 and a beta of 1.28. The business's 50 day moving average price is $84.11 and its 200-day moving average price is $74.31.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The business had revenue of $75.25 million for the quarter, compared to analysts' expectations of $44.17 million. During the same quarter in the previous year, the firm earned ($1.26) EPS. Arrowhead Pharmaceuticals's revenue was up 171.0% compared to the same quarter last year. On average, sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.62 earnings per share for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.